DAPT: Physiology and What Research Reports

What "DAPT" Refers To

The abbreviation DAPT carries two entirely separate meanings in the biomedical literature, and readers who meet the term in a search result or a forum post are often looking at one while reading about the other.

• DAPT the small molecule — N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, a synthetic dipeptide-like inhibitor of the γ-secretase enzyme complex. It is used in laboratories to switch off Notch signalling in cells and animals. Despite its peptide-style name, it is a small organic compound, not a therapeutic peptide.
• DAPT the clinical acronym — dual antiplatelet therapy, the combination of aspirin with a P2Y12 inhibitor used after coronary stenting or acute coronary syndrome. Almost all of the cardiology literature that mentions "DAPT score" or "short DAPT" is about this meaning.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medication. Neither meaning of DAPT describes a peptide sold or used for self-experimentation, and nothing here is a protocol.

Where It Fits in Physiology: γ-Secretase and Notch

DAPT the inhibitor is not produced by the body. What it acts on is endogenous. γ-Secretase is a multi-subunit membrane protease complex (presenilin, nicastrin and partners) that cleaves several transmembrane substrates, including Notch receptors and amyloid precursor protein.

When a Notch receptor engages a ligand on a neighbouring cell, γ-secretase releases the Notch intracellular domain, which travels to the nucleus and drives transcription of target genes such as the HES family. This pathway helps decide whether a progenitor cell divides, differentiates or stays quiescent, and it operates in skin and hair follicles, blood vessels, immune cells and the nervous system. Blocking γ-secretase pharmacologically prevents Notch domain release, so Notch target-gene output falls — which is why the compound is used as a Notch "off switch" in experiments.

How the inhibitor is studied

Typical readouts in the published work include cell proliferation and migration assays, Notch target-gene and protein levels such as HES-1, inflammatory markers, and histology of regenerating tissue. In the cadmium study, researchers reported that DAPT attenuated cadmium-induced toxicity in mice by inhibiting inflammation and the Notch/HES-1 signalling axis (PMID 35571137), which illustrates the standard design: an injury model, a Notch-pathway readout, and a comparison with untreated animals.

What Studies Report: DAPT as a γ-Secretase Inhibitor

Proliferation in tumour cell models

One study reported that DAPT suppressed the proliferation of the human glioma cell line SHG-44 (PMID 25063285). In non-small-cell lung cancer cells, researchers reported that p53 regulated the effects of DAPT on Rac1 activation and cell migration, meaning the response to the inhibitor depended on the genetic background of the cells rather than being uniform (PMID 36923886). These are laboratory findings in cultured cells; they describe pathway biology and are not statements about treatment of disease in people.

Stem cells, skin and hair follicles

Because Notch helps govern progenitor-cell fate, DAPT has been used to interrogate stem-cell behaviour. A dermatology paper examined DAPT in the control of human hair follicle stem cell proliferation and differentiation (PMID 25254004). The interest there was mechanistic — mapping how Notch inhibition shifts follicle stem cells between dividing and differentiating states.

Vascular tissue engineering

In regenerative-biomaterials work, researchers reported that VEGF combined with DAPT promoted tissue regeneration and remodelling in vascular grafts (PMID 37899954). That study pairs a growth factor with Notch inhibition in an implanted scaffold, a combination approach rather than a systemic drug.

What Studies Report: DAPT as Dual Antiplatelet Therapy

The cardiology literature using the same four letters addresses a different question: how long aspirin plus a P2Y12 inhibitor should continue after stenting, balancing clot risk against bleeding risk. Readers searching "DAPT" will frequently land on this body of work.

Two decision tools dominate. The DAPT score was externally validated in a nationwide population (PMID 30158058), and a separate group described a simplified 4-item PRECISE-DAPT score intended for duration decision-making (PMID 32151822). A Canadian randomised substudy tested whether providing a DAPT score to cardiologists changed extension of dual antiplatelet therapy beyond one year after acute coronary syndrome (PMID 34993458), an example of implementation research rather than drug testing.

Duration itself has been studied directly. One trial compared 3-month with 1-month dual antiplatelet therapy in patients at high bleeding risk undergoing everolimus-eluting stent implantation (PMID 34503737). A 2024 systematic review and meta-analysis examined P2Y12 inhibitor monotherapy after short dual antiplatelet therapy in acute coronary syndrome (PMID 39054275). The consistent theme across this literature is that duration is individualised using risk estimates, not fixed.

Safety and Tolerability: What Studies Report

The two meanings carry different safety literatures, and conflating them is the most common error readers make.

For the γ-secretase inhibitor, the verified studies summarised here were mechanistic. They reported pathway and tissue effects — suppressed glioma cell proliferation (PMID 25063285) and reduced inflammation with Notch/HES-1 inhibition in cadmium-exposed mice (PMID 35571137) — rather than human tolerability outcomes. Because Notch signalling is required for normal renewal of many tissues, the mechanistic literature treats broad Notch blockade as biologically consequential, and the compound appears in these papers as a laboratory reagent, not an approved medicine.

For dual antiplatelet therapy, bleeding is the defining trade-off, which is precisely why risk scores exist: the PRECISE-DAPT work was framed around duration decision-making (PMID 32151822), and the everolimus-eluting stent trial specifically enrolled patients at high bleeding risk to compare 3-month and 1-month durations (PMID 34503737). The 2024 meta-analysis examined whether stepping down to P2Y12 inhibitor monotherapy after a short dual-therapy period was a viable strategy in acute coronary syndrome (PMID 39054275). Antiplatelet decisions of this kind are made by treating clinicians.

Why the Term Matters in Peptide Reading

DAPT appears in peptide-adjacent discussion for three reasons. First, its chemical name looks peptide-like, so it is sometimes mislabelled as a peptide. Second, Notch inhibition overlaps with topics peptide readers follow — hair follicle stem cells (PMID 25254004) and vascular tissue remodelling alongside growth factors (PMID 37899954). Third, search results mix the compound with the cardiology acronym, so mechanistic cell work and stent trials appear side by side. Reading the journal and title before the abstract is usually enough to tell which DAPT a paper means.

References

• A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making (American Heart Journal, 2020)
• DAPT Attenuates Cadmium-Induced Toxicity in Mice by Inhibiting Inflammation and the Notch/HES-1 Signaling Axis (Frontiers in Pharmacology, 2022)
• External Validation of the DAPT Score in a Nationwide Population (Journal of the American College of Cardiology, 2018)
• P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis (European Heart Journal Cardiovascular Pharmacotherapy, 2024)
• 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation (JACC: Cardiovascular Interventions, 2021)
• DAPT suppresses the proliferation of human glioma cell line SHG-44 (Asian Pacific Journal of Tropical Medicine, 2014)
• DAPT in the control of human hair follicle stem cell proliferation and differentiation (Postepy Dermatologii i Alergologii, 2014)
• VEGF combined with DAPT promotes tissue regeneration and remodeling in vascular grafts (Regenerative Biomaterials, 2023)
• p53 regulates the effects of DAPT on Rac1 activation and migration of non-small-cell lung cancer cells (Heliyon, 2023)
• Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS (CJC Open, 2021)